文献速递肺外科

新辅助免疫治疗后微创肺叶切除术治疗非小细胞肺癌的安全性与可行性

Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-12-16

本研究基于美国国家癌症数据库(2010-2018年),纳入4229例I-III期可切除非小细胞肺癌患者,其中218例(5%)接受新辅助免疫治疗,4011例(95%)接受新辅助单纯化疗。倾向性评分匹配分析显示,免疫治疗组与化疗组在微创肺叶切除术比例(60.8% vs 51.6%;P=0.11)、中转开胸率(14% vs 15%,P=0.83;比值比1.1;95%置信区间0.51-2.24)及围手术期结局方面均无显著差异;在仅接受新辅助免疫治疗的患者亚组分析中,开胸与微创肺叶切除术的病理及围手术期结局亦无差异。结论认为,新辅助免疫治疗未增加开胸需求、微创中转开胸或围手术期结局不佳的风险。

要点

  • 倾向性评分匹配后,新辅助免疫治疗组与单纯化疗组的微创肺叶切除术比例无显著差异(60.8% vs 51.6%;P=0.11)。
  • 两组微创中转开胸率无显著差异(14% vs 15%,P=0.83;比值比1.1;95%置信区间0.51-2.24)。
  • 仅接受新辅助免疫治疗的患者中,开胸与微创肺叶切除术的病理及围手术期结局无差异。

核心结论

  • 在新辅助免疫治疗后,可切除非小细胞肺癌患者并未增加开胸需求、微创中转开胸或围手术期结局不佳的风险。

研究设计与样本

  • 基于美国国家癌症数据库(2010-2018年)的回顾性队列研究,纳入I-III期非小细胞肺癌行肺叶切除术前接受免疫治疗联合或不联合化疗、或单纯化疗的患者。
  • 共识别4229例患者,其中218例(5%)接受新辅助免疫治疗,4011例(95%)接受新辅助单纯化疗;采用倾向性评分匹配评估微创手术比例、中转率及围手术期结局,并比较新辅助免疫治疗后开胸与微创肺叶切除术的围手术期结局。

主要发现

  • 倾向性评分匹配分析中,免疫治疗组与单纯化疗组的微创肺叶切除术比例无显著差异(60.8% vs 51.6%;P=0.11)。
  • 两组微创中转开胸率无显著差异(14% vs 15%,P=0.83;比值比1.1;95%置信区间0.51-2.24),淋巴结降期、切缘阳性、30天再入院及30天和90天死亡率亦无显著差异。
  • 仅在接受新辅助免疫治疗的患者亚组分析中,开胸肺叶切除术与微创肺叶切除术的病理或围手术期结局无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the feasibility of minimally invasive surgery (MIS) and perioperative outcomes following neoadjuvant immunotherapy for resectable non-small cell lung cancer (NSCLC). METHODS: Patients with stage I to III NSCLC treated with immunotherapy with or without chemotherapy or chemotherapy alone prior to lobectomy were identified in the National Cancer Database (2010-2018). The percentage of operations performed minimally invasively, conversion rates, and perioperative outcomes were evaluated using propensity-score matching. Propensity-score matching was also used to compare perioperative outcomes between patients who underwent an open lobectomy and those who underwent an MIS lobectomy after neoadjuvant immunotherapy. RESULTS: Of the 4229 patients identified, 218 (5%) received neoadjuvant immunotherapy and 4011 (95%) received neoadjuvant chemotherapy alone. There was no difference in the rate of MIS lobectomy among patients who received immunotherapy compared with those who received chemotherapy alone in propensity score-matched analysis (60.8% vs 51.6%; P = .11). There also were no significant differences in the rate of conversion from MIS to open lobectomy (14% vs 15%, P = .83; odds ratio, 1.1; 95% confidence interval, 0.51-2.24) or in nodal downstaging, margin positivity, 30-day readmission, and 30- and 90-day mortality between the 2 groups. In a subgroup analysis of only patients treated with neoadjuvant immunotherapy, there were no differences in pathologic or perioperative outcomes between patients who underwent open lobectomy and those who underwent MIS lobectomy. CONCLUSIONS: In this national analysis, neoadjuvant immunotherapy for resectable NSCLC was not associated with an increased likelihood of the need for thoracotomy, conversion from MIS to open lobectomy, or inferior perioperative outcomes.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mathey-Andrews C, McCarthy M, Potter AL, et al. Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022. PMID: 36653251. doi:10.1016/j.jtcvs.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。